zoledronic acid has been researched along with Bone Marrow Diseases in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 4 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, Y; Ji, Q; Liu, B; Liu, D; Liu, M; Yang, Q; Yang, Z; Zhang, B; Zhou, S | 1 |
| Aitken, D; Antony, B; Blizzard, L; Cai, G; Cicuttini, F; Hill, C; Jones, G; Laslett, LL; March, L; Martel-Pelletier, J; Pelletier, JP; Wang, Y; Winzenberg, T; Wluka, AE | 1 |
| Aitken, D; Cai, G; Cicuttini, F; Hill, C; Jones, G; Laslett, LL; March, L; Martel-Pelletier, J; Pelletier, JP; Wluka, AE | 1 |
| Appelt, KA; Meier, C; Müller, F; Suhm, N | 1 |
| Li, Y; Liu, F; Liu, M; Mao, Y; Wang, X; Yu, D; Zhao, X; Zhu, Z | 1 |
| Cullen, N; Ferrero, A; Goldberg, A; Rose, B; Singh, D | 1 |
| Dalbeth, N; Doyle, A; Exeter, M; Jones, P; Lloyd, R; Lobo, M; McQueen, F; Reid, IR; Robinson, E; Taylor, WJ | 1 |
| Boon, P; Doré, DA; Jones, G; Laslett, LL; Quinn, SJ; Ryan, E; Winzenberg, TM | 1 |
| Berger, SA; Bogoch, ER; Fornasier, VL; Lee, TC | 1 |
3 trial(s) available for zoledronic acid and Bone Marrow Diseases
| Article | Year |
|---|---|
Effect of Intravenous Zoledronic Acid on Tibiofemoral Cartilage Volume Among Patients With Knee Osteoarthritis With Bone Marrow Lesions: A Randomized Clinical Trial.
Topics: Aged; Bone Density Conservation Agents; Bone Marrow; Bone Marrow Diseases; Cartilage, Articular; Double-Blind Method; Female; Humans; Infusions, Intravenous; Knee Joint; Male; Middle Aged; Osteoarthritis, Knee; Treatment Failure; Zoledronic Acid | 2020 |
Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: the Zoledronic Acid in Psoriatic Arthritis (ZAPA) Study.
Topics: Adult; Arthritis, Psoriatic; Bone Density Conservation Agents; Bone Marrow Diseases; Diphosphonates; Disease Progression; Edema; Epidemiologic Methods; Female; Finger Joint; Humans; Imidazoles; Magnetic Resonance Imaging; Male; Middle Aged; Treatment Outcome; Wrist Joint; Zoledronic Acid | 2011 |
Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial.
Topics: Acute-Phase Reaction; Aged; Arthralgia; Bone Density Conservation Agents; Bone Marrow Diseases; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Infusions, Intravenous; Knee Joint; Male; Middle Aged; Osteoarthritis, Knee; Outcome Assessment, Health Care; Pain Measurement; Treatment Outcome; Zoledronic Acid | 2012 |
6 other study(ies) available for zoledronic acid and Bone Marrow Diseases
| Article | Year |
|---|---|
Calcium phosphate hybrid micelles inhibit orthotopic bone metastasis from triple negative breast cancer by simultaneously killing cancer cells and reprogramming the microenvironment of bone resorption and immunosuppression.
Topics: Bone Marrow Diseases; Bone Neoplasms; Calcium Phosphates; Cell Line, Tumor; Docetaxel; Humans; Immunosuppression Therapy; Micelles; Osteolysis; Triple Negative Breast Neoplasms; Tumor Microenvironment; Zoledronic Acid | 2023 |
The association between change in bone marrow lesion size and change in tibiofemoral cartilage volume and knee symptoms.
Topics: Arthralgia; Bone Density Conservation Agents; Bone Marrow; Bone Marrow Diseases; Cartilage, Articular; Double-Blind Method; Female; Femur; Glucocorticoids; Humans; Knee Joint; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Multicenter Studies as Topic; Osteoarthritis, Knee; Randomized Controlled Trials as Topic; Tibia; Time Factors; Zoledronic Acid | 2021 |
Zoledronic acid is more efficient than ibandronic acid in the treatment of symptomatic bone marrow lesions of the knee.
Topics: Aged; Arthralgia; Biomarkers; Bone Density Conservation Agents; Bone Marrow Diseases; Collagen Type I; Denosumab; Dietary Supplements; Diphosphonates; Female; Humans; Ibandronic Acid; Male; Middle Aged; Peptide Fragments; Peptides; Procollagen; Retrospective Studies; Vitamin D; Zoledronic Acid | 2020 |
The inhibition of subchondral bone lesions significantly reversed the weight-bearing deficit and the overexpression of CGRP in DRG neurons, GFAP and Iba-1 in the spinal dorsal horn in the monosodium iodoacetate induced model of osteoarthritis pain.
Topics: Alkylating Agents; Animals; Arthritis, Experimental; Behavior, Animal; Bone Density Conservation Agents; Bone Marrow Diseases; Calcitonin Gene-Related Peptide; Calcium-Binding Proteins; Chronic Pain; Diphosphonates; DNA-Binding Proteins; Fluorescent Antibody Technique; Ganglia, Spinal; Glial Fibrillary Acidic Protein; Imidazoles; Iodoacetates; Knee Joint; Male; Microfilament Proteins; Neurons; Osteoarthritis; Rats; Rats, Sprague-Dawley; Spinal Cord; Weight-Bearing; X-Ray Microtomography; Zoledronic Acid | 2013 |
Bone Marrow Edema Syndrome of the Foot and Ankle: Mid- to Long-Term Follow-up in 18 Patients.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Bone Marrow Diseases; Diphosphonates; Edema; Female; Follow-Up Studies; Foot Diseases; Foot Orthoses; Humans; Imidazoles; Immobilization; Male; Middle Aged; Pain Management; Retrospective Studies; Zoledronic Acid | 2016 |
Articular damage is associated with intraosseous inflammation in the subchondral bone marrow of joints affected by experimental inflammatory arthritis and is modified by zoledronate treatment.
Topics: Animals; Arthritis, Experimental; Bone Density Conservation Agents; Bone Marrow; Bone Marrow Diseases; Carrageenan; CD11b Antigen; CD3 Complex; CD4 Antigens; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Inflammation; Joints; Rabbits; Rats; Rats, Sprague-Dawley; Spleen; Zoledronic Acid | 2007 |